The Prognostic Impact of Synchronous Ipsilateral Multiple Breast Cancer: Survival Outcomes according to the Eighth American Joint Committee on Cancer Staging and Molecular Subtype
Background In the current American Joint Committee on Cancer staging system of breast cancer, only tumor size determines T-category regardless of whether the tumor is single or multiple. This study evaluated if tumor multiplicity has prognostic value and can be used to subclassify breast cancer. Methods We included 5,758 patients with invasive breast cancer who underwent surgery at Samsung Medical Center, Seoul, Korea, from 1995 to 2012. Results Patients were divided into two groups according to multiplicity (single, n = 4,744; multiple, n = 1,014). Statistically significant differences in lymph node involvement and lymphatic invasion were found between the two groups (p < .001). Patients with multiple masses tended to have luminal A molecular subtype (p < .001). On Kaplan-Meier survival analysis, patients with multiple masses had significantly poorer disease-free survival (DFS) (p = .016). The prognostic significance of multiplicity was seen in patients with anatomic staging group I and prognostic staging group IA (p = .019 and p = .032, respectively). When targeting patients with T1-2 N0 M0, hormone receptor–positive, and human epidermal growth factor receptor 2 (HER2)–negative cancer, Kaplan-Meier survival analysis also revealed significantly reduced DFS with multiple cancer (p = .031). The multivariate analysis indicated that multiplicity was independently correlated with worse DFS (hazard ratio, 1.23; 95% confidence interval, 1.03 to 1.47; p = .025). The results of this study indicate that tumor multiplicity is frequently found in luminal A subtype, is associated with frequent lymph node metastasis, and is correlated with worse DFS. Conclusions Tumor multiplicity has prognostic value and could be used to subclassify invasive breast cancer at early stages. Adjuvant chemotherapy would be necessary for multiple masses of T1–2 N0 M0, hormone-receptor-positive, and HER2-negative cancer..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2018 |
|---|---|
| Erschienen: |
2018 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:52 |
|---|---|
| Enthalten in: |
Journal of Pathology and Translational Medicine - 52(2018), 6, Seite 396-403 |
| Sprache: |
Englisch ; Koreanisch |
|---|
| Beteiligte Personen: |
Jinah Chu [VerfasserIn] |
|---|
| Links: |
doi.org [kostenfrei] |
|---|
| Themen: |
Breast neoplasms |
|---|
| doi: |
10.4132/jptm.2018.10.03 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
DOAJ001518828 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ001518828 | ||
| 003 | DE-627 | ||
| 005 | 20230309163305.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230225s2018 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.4132/jptm.2018.10.03 |2 doi | |
| 035 | |a (DE-627)DOAJ001518828 | ||
| 035 | |a (DE-599)DOAJf599b4bddf244c8f952d895cca7a37bb | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng |a kor | ||
| 050 | 0 | |a RB1-214 | |
| 100 | 0 | |a Jinah Chu |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The Prognostic Impact of Synchronous Ipsilateral Multiple Breast Cancer: Survival Outcomes according to the Eighth American Joint Committee on Cancer Staging and Molecular Subtype |
| 264 | 1 | |c 2018 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Background In the current American Joint Committee on Cancer staging system of breast cancer, only tumor size determines T-category regardless of whether the tumor is single or multiple. This study evaluated if tumor multiplicity has prognostic value and can be used to subclassify breast cancer. Methods We included 5,758 patients with invasive breast cancer who underwent surgery at Samsung Medical Center, Seoul, Korea, from 1995 to 2012. Results Patients were divided into two groups according to multiplicity (single, n = 4,744; multiple, n = 1,014). Statistically significant differences in lymph node involvement and lymphatic invasion were found between the two groups (p < .001). Patients with multiple masses tended to have luminal A molecular subtype (p < .001). On Kaplan-Meier survival analysis, patients with multiple masses had significantly poorer disease-free survival (DFS) (p = .016). The prognostic significance of multiplicity was seen in patients with anatomic staging group I and prognostic staging group IA (p = .019 and p = .032, respectively). When targeting patients with T1-2 N0 M0, hormone receptor–positive, and human epidermal growth factor receptor 2 (HER2)–negative cancer, Kaplan-Meier survival analysis also revealed significantly reduced DFS with multiple cancer (p = .031). The multivariate analysis indicated that multiplicity was independently correlated with worse DFS (hazard ratio, 1.23; 95% confidence interval, 1.03 to 1.47; p = .025). The results of this study indicate that tumor multiplicity is frequently found in luminal A subtype, is associated with frequent lymph node metastasis, and is correlated with worse DFS. Conclusions Tumor multiplicity has prognostic value and could be used to subclassify invasive breast cancer at early stages. Adjuvant chemotherapy would be necessary for multiple masses of T1–2 N0 M0, hormone-receptor-positive, and HER2-negative cancer. | ||
| 650 | 4 | |a Breast neoplasms | |
| 650 | 4 | |a Multiplicity | |
| 650 | 4 | |a Disease-free survival | |
| 650 | 4 | |a Prognosis | |
| 650 | 4 | |a Molecular subtype | |
| 653 | 0 | |a Pathology | |
| 700 | 0 | |a Hyunsik Bae |e verfasserin |4 aut | |
| 700 | 0 | |a Youjeong Seo |e verfasserin |4 aut | |
| 700 | 0 | |a Soo Youn Cho |e verfasserin |4 aut | |
| 700 | 0 | |a Seok-Hyung Kim |e verfasserin |4 aut | |
| 700 | 0 | |a Eun Yoon Cho |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t Journal of Pathology and Translational Medicine |d Korean Society of Pathologists & the Korean Society for Cytopathology, 2017 |g 52(2018), 6, Seite 396-403 |w (DE-627)DOAJ000047392 |x 23837845 |7 nnns |
| 773 | 1 | 8 | |g volume:52 |g year:2018 |g number:6 |g pages:396-403 |
| 856 | 4 | 0 | |u https://doi.org/10.4132/jptm.2018.10.03 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/f599b4bddf244c8f952d895cca7a37bb |z kostenfrei |
| 856 | 4 | 0 | |u http://www.jpatholtm.org/upload/pdf/jptm-2018-10-03.pdf |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/2383-7837 |y Journal toc |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/2383-7845 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 951 | |a AR | ||
| 952 | |d 52 |j 2018 |e 6 |h 396-403 | ||